Wikidata

(Q64150055)

English

A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

clinical trial

In more languages

Statements

short name
COMBI-i (English)
0 references
title
A Randomized, Double-blind, Placebo-controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib Versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma (English)
0 references
sponsor
Novartis
0 references
country
Argentina
0 references
Australia
0 references
Austria
0 references
Belgium
0 references
Brazil
0 references
Bulgaria
0 references
Canada
0 references
Chile
0 references
Denmark
0 references
France
0 references
Germany
0 references
Greece
0 references
Hungary
0 references
Israel
0 references
Italy
0 references
Japan
0 references
Mexico
0 references
Netherlands
0 references
Norway
0 references
Poland
0 references
Portugal
0 references
Spain
0 references
Sweden
0 references
Switzerland
0 references
Thailand
0 references
United Kingdom
0 references
start time
17 February 2017
0 references
end time
19 July 2019
0 references
number of participants
538
0 references
minimum age
18 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q64150055&oldid=1857568363"